Nanowire Sensor-based Assay for Detecting Dengue and Chikungunya Virus

项目摘要 登革热（DENV）和基孔肯雅病毒（CHIKV）主要由两种类型的蚊子传播， 埃及伊蚊和白纹伊蚊。感染登革病毒的患者可能会出现登革热， 登革出血热（DHF）和登革休克综合征（DSS）。DHF和DSS可能是致命的， 特别是在美国流行地区的公共卫生问题，非洲、亚洲和美洲。患者 CHIKV感染者经历类似于急性发热性疾病的症状-发烧和关节疼痛。例 截至2013年，CHIKV在美国呈上升趋势，当时报告了大量病例。当前没有任何 FDA批准的疫苗或抗病毒药物在美国可用于减轻这些病毒引起的症状。 疾病虽然病媒传播疾病的早期和准确检测与更好的结果相关，但没有单一的 实验室检测可以准确诊断和监测DENV和CHIKV。为了满足日益增长的 及时检测媒介传播的病毒，InnoSense LLC（ISL）及其合作者，科罗拉多州 大学，建议开发纳米VIR，一种创新的聚合物纳米线微电子生物传感器。 该生物传感器建立在ISL的新兴和成熟的聚合物纳米线技术的基础上。Nano-VIR预计 检测DENV和CHIKV的灵敏度为102-103基因组拷贝当量/ml， 30分钟内的特异性。在第一阶段，ISL的目标是：（1）制备聚合物纳米线生物传感器， DENV和CHIKV检测;（2）证明Nano-VIR准确检测DENV和CHIKV的能力。在 第二阶段，ISL将优化生物传感器在临床环境中的灵敏度，特异性，准确性和可靠性 用的是鉴证科的病人样本一旦优化，一个带有硬件和软件的原型将 开发用于在单一测定中检测DENV和CHIKV。

PROJECT SUMMARY The Dengue (DENV) and Chikungunya viruses (CHIKV) are primarily transmitted by two types of mosquitoes, the Aedes aegypti and the Aedes albopictus. Patients infected by DENV may experience dengue fever, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). DHF and DSS could be fatal and are of particular public health concern in endemic regions of the U.S., Africa, Asia, and the Americas. Patients infected by CHIKV experience symptoms similar to acute febrile illnesses – fever and joint pain. Cases of CHIKV are on the rise in the U.S. as of 2013 when a significant number of cases were reported. Currently, no FDA-approved vaccines or anti-viral drugs are available in U.S. to mitigate the symptoms caused by these viral diseases. While early and accurate detection of vector-borne illnesses correlates to better outcomes, no single laboratory test can accurately diagnose and monitor DENV and CHIKV. To address the growing need for timely detection of vector-borne viruses, InnoSense LLC (ISL) and its collaborator, Colorado State University, propose to develop Nano-VIR, an innovative polymer nanowire microelectronic biosensor. The biosensor builds upon ISL’s emerging and proven polymer nanowire technology. Nano-VIR is expected to detect DENV and CHIKV with a sensitivity of 102–103 genome copy equivalent/ml with ≥95% specificity within 30 minutes. In Phase I, ISL’s objectives are: (1) fabricate polymer nanowire biosensor for DENV and CHIKV detection; (2) demonstrate Nano-VIR’s capability to accurately detect DENV and CHIKV. In Phase II, ISL will optimize the sensitivity, specificity, accuracy and reliability of the biosensor in a clinical setting using patient samples from CSU. Once optimized, a prototype with accompanying hardware and software will be developed for detection of both DENV and CHIKV in a single assay.